ORBIMED ADVISORS LLC 4
4 · Sionna Therapeutics, Inc. · Filed Jul 9, 2026
Research Summary
AI-generated summary of this filing
Sionna Therapeutics Director OrbiMed Advisors Sells 85,918 Shares
What Happened
OrbiMed Advisors LLC (reported as a director-related reporting person) sold 85,918 shares of Sionna Therapeutics, Inc. (SION) on July 7, 2026. The shares were disposed at $44.86 each, generating proceeds of approximately $3,854,281. The filing classifies the transaction as an open-market or private sale and notes the sale occurred pursuant to a 10b5-1 trading plan.
Key Details
- Transaction date: 2026-07-07; Filing date: 2026-07-09 (appears to be filed within the typical two-business-day Form 4 window).
- Price and quantity: 85,918 shares sold at $44.86 per share; total proceeds ≈ $3,854,281.
- Method: Open market or private sale executed pursuant to a 10b5-1 plan (Footnote F1).
- Ownership structure: The shares are held of record by OrbiMed Private Investments VIII, LP (OPI VIII); OrbiMed Advisors and GP VIII are related entities that may be deemed to have voting/investment power (Footnote F2). The report is jointly filed; reporting persons disclaim beneficial ownership except for any pecuniary interest (Footnote F3).
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
Context
This was a sale by an institutional reporting entity rather than a direct personal purchase by an individual executive. Sales under pre-established 10b5-1 plans are commonly scheduled in advance and are often considered routine disposition rather than a direct signal of management sentiment. Retail investors should view this as a supply-side transaction by an institutional holder; it does not, by itself, indicate company performance or insider confidence.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-07-07$44.86/sh−85,918$3,854,281→ 2,469,959 total(indirect: See footnotes)
Footnotes (3)
- [F1]These securities were sold pursuant to a 10b5-1 plan.
- [F2]These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- [F3]This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.